ClinicalTrials.gg
Active, not recruitingNCT03831386NEWTONUpdated Aug 10, 2026

Gravity Versus Vacuum Based Indwelling Tunneled Pleural Drainage System

An interventional study of Vacuum-Based IPC and Gravity-Based IPC in Pleural Effusion, sponsored by Johns Hopkins University. Active, not recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Pleural Effusion with a site in United States — 6 open to participants now, 9 under way, none of them phase 3. Pleural Effusion · United States.

Planned enrollment
7th of 34
200 · median 42
Started
2019
with 1 other
No phase
18 of 45
3 open now
Registered
30th of 45
by date

Among the 45 studies in Pleural Effusion with a site in United States, this one is the 7th largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2019, is one of 18 with no phase, and was the 30th registered.

Pleural Effusion

241 studies on the registry are indexed under Pleural Effusion; 49 are open to participants now.

Browse Pleural Effusion studies →

Open to participants now

6 of the 45 studies in Pleural Effusion with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Pleural Effusion studies recruiting now, 25 (83%) set no upper age limit and 2 (7%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Pleural Effusion with a site in United States, or all of them as a file.
02

Study summary

Malignant pleural effusion remains a debilitating complication of end stage cancer, which can be greatly improved by the introduction of the indwelling tunneled pleural catheter (IPC). However, there is no standard of care regarding drainage and limited data on the utility of different drainage techniques. In addition, many patients develop discomfort and chest pain during drainage. The investigators propose to evaluate gravity drainage and suction drainage on quality of life measures and outcomes.

Read the detailed description

Indwelling tunneled pleural catheters (IPCs) are used to alleviate pleural effusion as a first-line therapeutic (albeit palliative) intervention. Limited data currently exists on drainage techniques and the impact the techniques may have on quality of life. Current recommendations for IPC drainage range from daily drainage to once a week drainage, as well as only when needed for dyspnea. It has been theorized that active drainage of effusions may have an impact on the development of chest discomfort/pain, whereas passive regimens may allow for more gradual intrathoracic pleural changes and potentially offer a difference in drainage discomfort.

The objective of this investigation is to compare different drainage strategies of indwelling pleural catheters (IPCs) regarding patient quality of life and outcomes. Patients will undergo placement of a pleural catheter as per standard institutional protocol. Patients will be randomized on a 1:1 basis into the suction drainage (active) arm or the gravity drainage (passive) arm. Patients will receive follow-up at two weeks, four weeks, twelve weeks and then as needed post IPC placement per standard clinical protocol. All patients will be asked to fill out quality of life questionnaires and update drainage diary information with patient's providers.

Patients will undergo standard care treatment throughout the disease course and no different interventions regarding the pleural disease will be performed as a result of enrollment within this study. Study interventions/procedures will consist of questionnaires and patient self-reported documentation regarding patient's care and outcomes.

03

Conditions studied

  • Pleural Effusion

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical indications for placement of IPC for malignant pleural effusion

    a. Pleural effusion with symptomatic improvement in dyspnea after drainage of ipsilateral effusion

  • Clinically confident symptomatic malignant pleural effusion

    1. Histocytological proof of pleural
    2. Recurrent large pleural effusion in context of proven cancer outside the pleural space
  • Plans for placement of IPC within ten days of enrollment
  • Age > 17 years
  • Sufficient fluid on ultrasound to allow for safe insertion of IPC

Exclusion criteria

Exclusion Criteria:

  • Recent (less than 60 days) thoracic surgery or chest trauma causing chronic pain
  • Pregnant or lactating mothers
  • Previous ipsilateral chemical pleurodesis
  • Current contralateral indwelling pleural catheter
  • Known rib or thoracic skeletal causing pain
  • Concern for active pleural infection
  • Respiratory failure
  • Irreversible bleeding diathesis
  • Inability to provide care for indwelling tunneled pleural catheter
  • Significantly loculated pleural space precluding drainage of pleural space, for which IPC alone will likely not offer symptomatic benefit
  • Estimated of \< 30 days (however, active enrollment in hospice program is not an exclusion criteria)
  • Inability to read/understand/write in the English language
  • Inability to follow-up for appointments/protocol
  • Subject has any clinical condition, diagnosis, or social circumstance that, in the opinion of the investigator would mean participation in the study would be .
  • Enrollment in alternative pleural catheter trial that would preclude enrollment within this trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Vacuum

    The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care. Participants in this arm will undergo Vacuum-Based IPC.

    Procedure: Vacuum-Based IPC

  • Experimental
    Gravity

    The pleural fluid will be drained using gravity drainage to a bag positioned at bedside. Participants in this arm will undergo Gravity-Based IPC.

    Procedure: Gravity-Based IPC

Interventions

  • ProcedureVacuum-Based IPC

    An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via suction.

  • ProcedureGravity-Based IPC

    An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via gravity.

06

What researchers measure

Primary outcomes

  1. Change in chest pain as assessed by Visual Analog Scale (VAS)

    The primary endpoint is the difference between the mean daily change in pain score during IPC drainage via the vacuum bottle technique and IPC drainage via the gravity bag technique over two weeks after IPC placement. Pre-drainage and post-drainage pain scores will be recorded each day of IPC placement. Measurements are in millimeters along a 10 cm VAS. VAS score is a range of 0 to 100. Lower limit is 0, meaning no pain; upper limit is 100, meaning extreme pain.

    Time frame: Daily, up to 2 weeks

Secondary outcomes

  1. Change in mean difference in chest pain as assessed by VAS

    This secondary endpoint is the difference between the change in pain scores via vacuum bottle vs. gravity bag pre-IPC placement to the last available score after IPC placement. This last available score would be at 12 weeks or time of pleurodesis. Measurements are in millimeters along a 10 cm Visual Analog Scale (VAS). VAS score is a range of 0 to 100. Lower limit is 0, meaning no pain; upper limit is 100, meaning extreme pain.

    Time frame: pre-IPC placement, 12 weeks post IPC placement or time of pleurodesis

  2. Change in SF 36-Item Health Survey score

    This secondary endpoint is the difference between SF 36-Item Health Survey 1.0 scores via vacuum bottle vs. gravity bag from pre-IPC drainage to last available score after IPC placement (at 12 weeks or time of pleurodesis). Scoring is a 2-step process in which the numerical response from the Survey is first converted into a 0-100 scale (0 as lowest and 100 as highest possible score) using a conversion table by SF developers. These new values would be averaged according to their group identified in a second conversion table.

    Time frame: pre-IPC placement, 12 weeks post IPC placement or time of pleurodesis

  3. Change in Functional Assessment of Chronic Illness Therapy (FACIT)-Dyspnea survey score

    This secondary endpoint is the difference between FACIT-Dyspnea scores via vacuum bottle vs. gravity bag from pre-IPC drainage to the last available score after IPC placement (at 12 weeks or time of pleurodesis). Individual responses are converted into scores, then summed for an overall score. Scores range from 0 (lower limit) to 30 (high limit); the higher the score, the worse the dyspnea.

    Time frame: pre-IPC placement, 12 weeks post IPC placement or time of pleurodesis

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No — De-identified individual study data will be used for analysis by lead PI and analyst. However, study is using REDCap database system with restrictions so that researchers only see individual data from their own site.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Dec 2026, 95 months after the start.

Of 61 non-industry interventional studies with no phase under Pleural Effusion, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 52. This study's planned 95 months is above that.

Counting every sponsor, half of 63 studies reached it within 26 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2019
First posted
Feb 5, 2019
StartActual
Jan 31, 2019
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03831386
Collaborators
Rocket Medical plc, Swedish Medical Center, Medical University of South Carolina, University of Oxford, Vanderbilt University Medical Center, Northwest Community Healthcare
Responsible party
Sponsor
First posted
Feb 5, 2019
Start date
Jan 31, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 10, 2026

Study contacts

Lonny Yarmus, DO
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion